PURPLE BIOTECH LTD.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 40.0
- Dividend yield
- –
About Purple Biotech
Pharmaceutical Preparations, SIC 2834
Purple Biotech Ltd. is a clinical-stage biotechnology company engaged in the research, development, and commercialization of oncology treatments. Its product pipeline features CAPTN-3, a preclinical tri-specific antibody platform with lead candidates IM1240 and IM1305, as well as two clinical-stage oncology drug candidates, CM24 and NT219. The company focuses on developing these experimental therapies for cancer patients and potential biopharmaceutical commercialization partners, while none of its active product candidates are currently approved for marketing or commercial sale.
The company operates primarily from Israel, with corporate and research operations maintained through its Israeli headquarters. Purple Biotech is headquartered at 4 Oppenheimer Street, Science Park, Rehovot, Israel. In addition to its domestic operations and subsidiaries including TyrNovo, FameWave, and Immunorizon, the company previously established an international subsidiary, Purple Biotech GmbH, which is in the process of dissolution.
Summary of the business section of Purple Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PURPLE BIOTECH LTD.
- Founded
- 1968
- Headquarters
- Rehovot, L3
- Address
- 4 Oppenheimer Street, Science Park 7670104
- Phone
- 97239333121
- Website
- purple-biotech.com
- Employees
- 19, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Somekh Chaikin, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- PPBT
- Exchange
- Nasdaq
- IPO date
- Nov 23, 2015
- Shares outstanding
- 1.86B, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-10 reverse, Mar 2, 2026; 1-for-20 reverse, Sep 17, 2024; 1-for-10 reverse, Aug 21, 2020; 1-for-20 reverse, Mar 26, 2019
- SEC CIK
- 1614744
- CUSIP
- 74638P307
- ISIN
- US74638P3073
- LEI
- 5493008YRL2KK6TM3819
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gil Efron | Chief Executive Officer | 15,750,000 |
| Shai S. Lankry | Chief Financial Officer | 3,550,000 |
| Michael Schickler | Head of Clinical & Reg Affairs | 9,254,472 |
| Simcha Rock | Director | 3,207,690 |
| Suzana Zilberberg | Director | 3,062,500 |
| Ido Agmon | Director | 3,093,860 |
| Robert E. Gagnon | Director | 3,062,500 |
Employees
Headcount reported in annual reports
“in 2020 roughly one in every 19 people worldwide would either be diagnosed with a solid tumor or be a cancer survivor.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 10, 2020 | Name change | Name changed from Kitov Pharma Ltd. to PURPLE BIOTECH LTD. |
| Nov 23, 2020 | Delisting | Notice of delisting from exchange (Form 25) |
| Dec 21, 2017 | Name change | Name changed from Kitov Pharmaceuticals Holdings Ltd. to Kitov Pharma Ltd. |
| Nov 23, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 18, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |